Not available
Quote | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Last: | $20.80 |
---|---|
Change Percent: | 0.39% |
Open: | $20.41 |
Close: | $20.80 |
High: | $21.12 |
Low: | $20.36 |
Volume: | 853,587 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass. , April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire – Consistent safety and efficacy profiles across adult and pediatric populations – ȁ...
Message Board Posts | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION! $SNDX $STRO $MTEM $KRYS Clinical-Stage | AviseAnalytics | investorshangout | 10/05/2021 12:45:05 PM |
Nice rebound today for $SNDX, beat the street | dealerschool2006 | investorshub | 05/12/2021 8:13:51 PM |
$SNDX recovering from panic sale!!! | dealerschool2006 | investorshub | 04/28/2021 4:46:26 PM |
Panic sale for SNDX on positive results...May options | dealerschool2006 | investorshub | 04/20/2021 2:52:48 PM |
Its interesting how a company such as this | DaytraderJohn | investorshub | 04/29/2020 6:39:33 AM |
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass. , April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire – Consistent safety and efficacy profiles across adult and pediatric populations – ȁ...
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing ...